Piramal Pharma FY2026 results: PAT up, loss ₹326 cr

What Piramal Pharma reported for FY2026

Piramal Pharma Limited disclosed its audited financial results for the year ended March 31, 2026, along with a set of board and management updates. The company reported revenue and profit numbers for both standalone and consolidated accounts. On the leadership side, it confirmed re-appointments for executive and independent directors, and announced a change in the Company Secretary and Compliance Officer role. The disclosures were shared through stock exchange filings, with BSE referenced as the source for the core update. The mix of financial performance and governance changes is material for investors because it speaks to both near-term reported numbers and continuity of oversight. The announcements also include specific effective dates for appointments and operational updates.

Standalone performance: revenue and profit after tax

For FY2026, Piramal Pharma reported standalone revenue of ₹4,782.01 crore. Standalone profit after tax (PAT) stood at ₹700.01 crore for the year ended March 31, 2026. The company compared this with standalone PAT of ₹691.40 crore in the previous year, indicating a modest year-on-year increase. The update did not provide standalone quarterly break-up for Q4 within the same disclosure text provided here. It also did not specify drivers of the standalone PAT change, such as margins, finance costs, or tax items. Still, the standalone numbers provide a view of performance at the parent-company level. Investors often track standalone trends to understand dividend-paying capacity and the parent entity’s profitability.

Consolidated picture: revenue, net loss, and impairment

On a consolidated basis, Piramal Pharma reported FY2026 revenue of ₹8,869.08 crore. Despite the revenue base, the company disclosed a consolidated net loss after tax of ₹325.94 crore for the year. The filing attributed the consolidated loss to various operational and exceptional items. A key exceptional item highlighted was an impairment charge of ₹175.82 crore recognised during the year. The disclosure, as provided, did not specify the asset or business area where the impairment was booked. It also did not detail other exceptional items that may have contributed to the reported loss. The consolidated outcome is relevant because it reflects performance across subsidiaries and the broader group structure.

Board meeting and results process on the exchanges

Piramal Pharma had earlier intimated that its Board of Directors meeting was scheduled on April 28, 2026. The stated agenda included considering and approving the audited financial results (standalone and consolidated) for the quarter and financial year ended March 31, 2026. The exchange feed included multiple entries referencing this board meeting intimation during April 2026. The company also flagged that the trading window was closed from April 1, 2026 to April 30, 2026, inclusive. Separately, the company shared details of a results conference call scheduled for April 29, 2026 from 9:30 AM to 10:15 AM IST. The call note also mentioned dial-in availability across several geographies and the use of a pre-registration option to reduce waiting time. These steps are commonly used to ensure orderly dissemination of information and to enable investors and analysts to ask follow-up questions.

Re-appointment of Nandini Piramal as Chairperson and Executive Director

The company confirmed that Ms. Nandini Piramal has been re-appointed as a Whole-Time Director. Her designation was stated as Executive Director and Chairperson. The re-appointment term is for three years starting April 1, 2027. The disclosure indicates the board’s intent to maintain continuity in leadership at the chairperson and executive director level. The term start date being in FY2028 suggests the action is a forward-looking re-appointment decision rather than a change effective immediately. The filing does not provide additional details on board committee roles linked to this designation. It also does not include commentary on strategic priorities beyond noting that leadership transitions were approved to steer future growth. The re-appointment is a governance item that investors may track alongside financial performance because it affects accountability and strategic oversight.

Re-appointment of Peter DeYoung and independent directors

Alongside the chairperson re-appointment, Piramal Pharma stated that Mr. Peter DeYoung has been re-appointed as a Whole-Time Director. His designation was stated as Executive Director, and the term is for three years effective October 6, 2026. The board also approved the re-appointment of Independent Directors Mr. Sridhar Gorthi and Mr. Peter Stevenson. Their second term was approved for five consecutive years, effective March 30, 2027. These dates indicate a planned set of renewals rather than abrupt board changes. The disclosure also referenced that Mr. Subramanian Ramadorai ceased as an Independent Director with effect from February 9, 2026, upon completion of his term. As provided, the update noted he would not seek a second term. Taken together, the board actions show a mix of continuity and scheduled rotation in independent oversight.

Company Secretary change and compliance officer transition

Piramal Pharma announced a change in its Key Managerial Personnel for secretarial and compliance functions. Mr. Maneesh Sharma was appointed as the Company Secretary and Compliance Officer effective April 29, 2026. He is taking over from Ms. Pratibha Mishra, who served as the interim lead. The exchange feed also referenced an earlier appointment of Ms. Pratibha Mishra as Company Secretary and Compliance Officer with effect from February 21, 2026, reflecting the interim nature of the arrangement. The disclosure did not provide details on the outgoing company secretary’s resignation or reasons. Still, naming the effective date helps investors understand when the statutory compliance responsibility shifts. Such changes matter because the Company Secretary and Compliance Officer oversees regulatory filings, disclosure controls, and governance processes under listing regulations.

Registered office address update in Mumbai

The company also stated that it has updated its registered office address in Mumbai. The change will take effect on April 30, 2026. The updated location was specified as the Ananta Building, Piramal Corporate Park. The filing, as provided, did not specify the prior registered office address. It also did not indicate whether the change affects operational offices or is primarily a statutory registered-office update. For shareholders and market participants, the registered office address is relevant for formal communication, notices, and regulatory records. Effective-date clarity reduces ambiguity for compliance and stakeholder correspondence.

Key numbers and dates at a glance

Why the mix of results and governance changes matters

FY2026 presented a split picture between standalone profitability and consolidated losses. While standalone PAT increased to ₹700.01 crore, the consolidated result was a net loss of ₹325.94 crore, with an impairment charge of ₹175.82 crore highlighted in the filings. For investors, this gap can be important because consolidated accounts capture group-level realities, including exceptional items. At the same time, board and KMP decisions provide signals on how the company is setting up leadership continuity and compliance capacity. Scheduled re-appointments and clearly dated transitions reduce uncertainty around governance. The conference call timing, one day after the board meeting, also indicates a formal avenue for clarifications from management. What follows next, based on the disclosures provided, is the scheduled investor call on April 29, 2026 and the registered office change effective April 30, 2026.